Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer

Alfarsi, Lutfi and Johnston, Simon and Liu, Dong-Xu and Rakha, Emad and Green, Andrew (2018) Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology . ISSN 0309-0167

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (713kB) | Preview

Abstract

Endocrine therapy for oestrogen receptor‐positive (ER+) breast cancer (BC) is arguably the most successful targeted cancer therapy to date. Nevertheless, resistance to endocrine therapy still occurs in a significant proportion of patients, limiting its clinical utility. ER+ or luminal BC, which represents around three quarters of all breast malignancies, are biologically heterogeneous with no distinct, clinically defined sub‐classes able to predict the benefit of endocrine therapy in early settings. To improve patient outcomes, there is a clear need for improved understanding of the biology of the luminal BC, with subsequent translation into more effective methods of diagnosis to identify potential predictive biomarkers for endocrine therapy. This review summarises current knowledge of factors predictive of benefit of endocrine therapy, and discusses why molecular classification systems of BC have yet to be translated into the clinic.

Item Type: Article
Additional Information: This is the peer reviewed version of the following article: Alfarsi, Lutfi and Johnston, Simon and Liu, Dong-Xu and Rakha, Emad and Green, Andrew (2018) Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology. doi:10.1111/his.13523 , which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1111/his.13523. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Keywords: breast cancer, luminal, endocrine therapy response, resistance, oestrogen receptor, predictive biomarker
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Cancer and Stem Cells
Identification Number: https://doi.org/10.1111/his.13523
Depositing User: Eprints, Support
Date Deposited: 17 Apr 2018 08:20
Last Modified: 30 Mar 2019 04:30
URI: http://eprints.nottingham.ac.uk/id/eprint/51192

Actions (Archive Staff Only)

Edit View Edit View